1FG0 Stock Chart & Stats
€6.60
-€0.15(-2.50%)
At close: 4:00 PM EDT
€6.60
-€0.15(-2.50%)
Day’s Range― - ―
52-Week Range€5.35 - €10.10
Previous CloseN/A
Volume0.00
Average Volume (3M)2.00
Market Cap
€27.45M
Enterprise Value-€38.76
Total Cash (Recent Filing)€91.32M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)0.1
Beta0.91
Next Earnings
Nov 09, 2026EPS Estimate
-3.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)58.19
Shares Outstanding4,049,124
10 Day Avg. Volume0
30 Day Avg. Volume2
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-1.18
Price to Sales (P/S)5.51
P/FCF Ratio-7.38
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€34.03Price Target Upside415.61% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-11.84
Revenue Forecast (FY)€5.83M
Bulls Say, Bears Say
Bulls Say
Differentiated CD46 PipelineKyntra’s non-PSMA CD46 strategy combines an ADC with companion PET imaging, while Phase II enrollment and a Q4 2026 interim readout create a defined development path. Early response and rPFS signals provide evidence of clinical potential, although validation remains ahead.
Cash Runway Into 2028The reported liquidity position and expected runway into 2028 give Kyntra time to advance its clinical programs toward important readouts without an immediate financing need indicated in the guidance. This supports more deliberate development and capital-allocation decisions.
Lower Future Financing ObligationsThe amended revenue-interest agreement materially reduces the company’s future payment burden and eliminates true-up payments. Retaining subsequent EVRENZO royalties after the remaining cap is reached could improve long-term liquidity and preserve more economics from the asset.
Bears Say
Contracting Revenue And Weak Operating ProfitabilitySustained revenue contraction and sharply lower gross margin weaken the operating foundation of the business. Large operating losses indicate that reported earnings are not yet supported by the core operation, increasing dependence on pipeline progress and future commercialization success.
Ongoing Cash Burn And Negative EquityContinued cash consumption reduces financial flexibility even after debt reduction, while negative shareholders’ equity reflects an accumulated deficit and limited capital cushion. Together, these conditions can constrain investment capacity and keep funding risk relevant as programs advance.
Roxadustat Funding And Economics RiskRoxadustat’s registrational path is not fully self-funded on disclosed terms, creating a strategic decision between raising capital and surrendering economics. Either route could reduce Kyntra’s retained value or pressure liquidity while the Phase III program is advanced.
Kyntra Bio News
1FG0 FAQ
What was Kyntra Bio’s price range in the past 12 months?
Kyntra Bio lowest stock price was €5.35 and its highest was €10.10 in the past 12 months.
What is Kyntra Bio’s market cap?
Kyntra Bio’s market cap is €27.45M.
When is Kyntra Bio’s upcoming earnings report date?
Kyntra Bio’s upcoming earnings report date is Nov 09, 2026 which is in 53 days.
How were Kyntra Bio’s earnings last quarter?
Kyntra Bio released its earnings results on Aug 13, 2026. The company reported €2.559 earnings per share for the quarter, beating the consensus estimate of -€2.753 by €5.312.
Is Kyntra Bio overvalued?
According to Wall Street analysts Kyntra Bio’s price is currently Undervalued.
Does Kyntra Bio pay dividends?
Kyntra Bio does not currently pay dividends.
What is Kyntra Bio’s EPS estimate?
Kyntra Bio’s EPS estimate is -3.16.
How many shares outstanding does Kyntra Bio have?
Kyntra Bio has 4,049,124 shares outstanding.
What happened to Kyntra Bio’s price movement after its last earnings report?
Kyntra Bio reported an EPS of €2.559 in its last earnings report, beating expectations of -€2.753. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Kyntra Bio?
Currently, no hedge funds are holding shares in DE:1FG0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Kyntra Bio Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€34.03 (415.61% Upside)
€34.03 (415.61% Upside)
Blogger Sentiment
Bearish
DE:1FG0 Sentiment 100%
Sector Average 62%
Sector Average 62%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-33.88%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-43.23%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Kyntra Bio
Kyntra Bio, Inc. functions as a biopharmaceutical enterprise, encompassing the entire process from the initial discovery and rigorous development of innovative treatments to their ultimate market introduction. The company's scientific focus delves into the complex biology of hypoxia-inducible factors (HIF) and connective tissue growth factors (CTGF). Through this research, Kyntra Bio strives to create groundbreaking therapies aimed at tackling conditions like anemia, various fibrotic disorders, and different forms of cancer. Established by Thomas B. Neff on September 29, 1993, the firm's main offices are situated in San Francisco, California.
1FG0 Company Deck
1FG0 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented multiple meaningful clinical and operational positives: concrete Phase I/IST efficacy signals for FG-3246 (with a clear plan for a Phase II interim readout in Q4 2026), a finalized Phase III protocol and compelling subgroup data for roxadustat, a unique non-PSMA therapeutic + companion diagnostic position, and a positive swing to net income with a cash runway into 2028. Offsetting these were notable near-term financial headwinds (negative reported revenue and higher operating expenses), safety and biomarker confirmation risks that require larger data sets, enrollment and market dynamics uncertainty (Pluvicto adoption) and the dependence on partnering/capital for a registrational path for roxadustat. On balance, the highlights modestly outweigh the lowlights due to actionable clinical progress and a forthcoming near-term catalyst (FG-3246 interim) alongside sufficient cash runway to advance programs.View all DE:1FG0 earnings summaries1FG0 Stock 12 Month Forecast
Average Price Target
€34.03
▲(415.61% Upside)
Technical Analysis
Grace Therapeutics
―
―
OnKure Therapeutics
―
Senti Biosciences
―
Xilio Therapeutics
―